HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacologic inhibition of the CK2-mediated phosphorylation of B23/NPM in cancer cells selectively modulates genes related to protein synthesis, energetic metabolism, and ribosomal biogenesis.

Abstract
B23/NPM is a multifunctional nucleolar protein frequently overexpressed, mutated, or rearranged in neoplastic tissues. B23/NPM is involved in diverse biological processes and is mainly regulated by heteroligomer association and posttranslational modification, phosphorylation being a major posttranslational event. While the role of B23/NPM in supporting and/or driving malignant transformation is widely recognized, the particular relevance of its CK2-mediated phosphorylation remains unsolved. Interestingly, the pharmacologic inhibition of such phosphorylation event by CIGB-300, a clinical-grade peptide drug, was previously associated to apoptosis induction in tumor cell lines. In this work, we sought to identify the biological processes modulated by CIGB-300 in a lung cancer cell line using subtractive suppression hybridization and subsequent functional annotation clustering. Our results indicate that CIGB-300 modulates a subset of genes involved in protein synthesis (ES = 8.4, p < 0.001), mitochondrial ATP metabolism (ES = 2.5, p < 0.001), and ribosomal biogenesis (ES = 1.5, p < 0.05). The impairment of these cellular processes by CIGB-300 was corroborated at the molecular and cellular levels by Western blot (P-S6/P-4EBP1, translation), confocal microscopy (JC-1, mitochondrial potential), qPCR (45SrRNA/p21, ribosome biogenesis), and electron microscopy (nucleolar structure, ribosome biogenesis). Altogether, our findings provide new insights on the potential relevance of the CK2-mediated phosphorylation of B23/NPM in cancer cells, revealing at the same time the potentialities of its pharmacological manipulation for cancer therapy. Finally, this work also suggests several candidate gene biomarkers to be evaluated during the clinical development of the anti-CK2 peptide CIGB-300.
AuthorsYasser Perera, Seidy Pedroso, Orlando Borras-Hidalgo, Dania M Vázquez, Jamilet Miranda, Adelaida Villareal, Viviana Falcón, Luis D Cruz, Hernán G Farinas, Silvio E Perea
JournalMolecular and cellular biochemistry (Mol Cell Biochem) Vol. 404 Issue 1-2 Pg. 103-12 (Jun 2015) ISSN: 1573-4919 [Electronic] Netherlands
PMID25805179 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Nuclear Proteins
  • Peptides, Cyclic
  • Nucleophosmin
  • Casein Kinase II
  • CIGB-300
Topics
  • Apoptosis (drug effects)
  • Casein Kinase II (antagonists & inhibitors, genetics)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Energy Metabolism (genetics)
  • Humans
  • Neoplasms (drug therapy, genetics, pathology)
  • Nuclear Proteins (genetics, metabolism)
  • Nucleophosmin
  • Peptides, Cyclic (administration & dosage)
  • Phosphorylation (drug effects)
  • Ribosomes (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: